PE20141070A1 - Composiciones estables de povidona yodada con antiinflamatorios esteroideos o no esteroideos - Google Patents
Composiciones estables de povidona yodada con antiinflamatorios esteroideos o no esteroideosInfo
- Publication number
- PE20141070A1 PE20141070A1 PE2013002407A PE2013002407A PE20141070A1 PE 20141070 A1 PE20141070 A1 PE 20141070A1 PE 2013002407 A PE2013002407 A PE 2013002407A PE 2013002407 A PE2013002407 A PE 2013002407A PE 20141070 A1 PE20141070 A1 PE 20141070A1
- Authority
- PE
- Peru
- Prior art keywords
- concentration
- steroid
- inflammatory
- povidone iodine
- iodine compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 title abstract 2
- 229920000153 Povidone-iodine Polymers 0.000 title abstract 2
- 229960001621 povidone-iodine Drugs 0.000 title abstract 2
- 150000003431 steroids Chemical class 0.000 title abstract 2
- 230000003110 anti-inflammatory effect Effects 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- 206010010741 Conjunctivitis Diseases 0.000 abstract 1
- 206010010984 Corneal abrasion Diseases 0.000 abstract 1
- 208000028006 Corneal injury Diseases 0.000 abstract 1
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- WYQPLTPSGFELIB-JTQPXKBDSA-N Difluprednate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2CC[C@@](C(=O)COC(C)=O)(OC(=O)CCC)[C@@]2(C)C[C@@H]1O WYQPLTPSGFELIB-JTQPXKBDSA-N 0.000 abstract 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 abstract 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 abstract 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 abstract 1
- 229920001213 Polysorbate 20 Polymers 0.000 abstract 1
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract 1
- LRJOMUJRLNCICJ-JZYPGELDSA-N Prednisolone acetate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O LRJOMUJRLNCICJ-JZYPGELDSA-N 0.000 abstract 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 abstract 1
- 206010064996 Ulcerative keratitis Diseases 0.000 abstract 1
- 230000003444 anaesthetic effect Effects 0.000 abstract 1
- 230000000845 anti-microbial effect Effects 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000007717 corneal ulcer Diseases 0.000 abstract 1
- ALEXXDVDDISNDU-JZYPGELDSA-N cortisol 21-acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)C[C@@H]2O ALEXXDVDDISNDU-JZYPGELDSA-N 0.000 abstract 1
- 239000006184 cosolvent Substances 0.000 abstract 1
- 229960004875 difluprednate Drugs 0.000 abstract 1
- 229960001067 hydrocortisone acetate Drugs 0.000 abstract 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 206010023332 keratitis Diseases 0.000 abstract 1
- 229960004194 lidocaine Drugs 0.000 abstract 1
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 abstract 1
- 229960003744 loteprednol etabonate Drugs 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 229920000609 methyl cellulose Polymers 0.000 abstract 1
- 239000001923 methylcellulose Substances 0.000 abstract 1
- 235000010981 methylcellulose Nutrition 0.000 abstract 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 abstract 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 abstract 1
- 229940068977 polysorbate 20 Drugs 0.000 abstract 1
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 abstract 1
- 229960002800 prednisolone acetate Drugs 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 229960003981 proparacaine Drugs 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 229960002372 tetracaine Drugs 0.000 abstract 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
- A61K31/79—Polymers of vinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Anesthesiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA COMPOSICION OFTALMICA QUE COMPRENDE: A) POVIDONA-YODADA EN UNA CONCENTRACION DE 0.01% A 10%; B) UN ESTEROIDE TAL COMO ACETATO DE PREDNISOLONA, ETABONATO DE LOTEPREDNOL, DIFLUPREDNATO O ACETATO DE HIDROCORTISONA EN UNA CONCENTRACION DE 0.01% A 2%; C) UN ANESTESICO TOPICO TAL COMO PROPARACAINA, LIDOCAINA O TETRACAINA; D) UN CONSERVANTE ANTIMICROBIANO TAL COMO CLORURO DE BENZALCONIO, TIMEROSAL, METIL PARABENO, ENTRE OTROS, EN UNA CONCENTRACION DE 0.001% A 1.0%; E) UN COSOLVENTE O SURFACTANTE TAL COMO POLISORBATO 20, CICLODEXTRINA, ENTRE OTROS, EN UNA CONCENTRACION DE 0.01% A 2%; Y F) UN AGENTE QUE AUMENTA LA VISCOSIDAD TAL COMO ALCOHOL DE POLIVINILO, METIL CELULOSA, HIDROXIETIL CELULOSA, ENTRE OTROS, EN UNA CONCENTRACION DE 0.01% A 2%. DICHA COMPOSICION DE ADMINISTRACION TOPICA ES UTIL EN EL TRATAMIENTO DE UNA INFECCION POR MICOBACTERIAS TAL COMO CONJUNTIVITIS, ABRASION CORNEAL, QUERATITIS ULCERATIVA INFECCIOSA, QUERATITIS EPITELIAL
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161485475P | 2011-05-12 | 2011-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20141070A1 true PE20141070A1 (es) | 2014-09-14 |
Family
ID=47139697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2013002407A PE20141070A1 (es) | 2011-05-12 | 2012-05-11 | Composiciones estables de povidona yodada con antiinflamatorios esteroideos o no esteroideos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20150038473A1 (es) |
| EP (1) | EP2707006B1 (es) |
| JP (2) | JP6072009B2 (es) |
| KR (1) | KR101967938B1 (es) |
| CN (1) | CN103957922A (es) |
| AR (1) | AR086399A1 (es) |
| AU (3) | AU2012253335B2 (es) |
| BR (1) | BR112013028735A2 (es) |
| CA (1) | CA2835343A1 (es) |
| CL (1) | CL2013003016A1 (es) |
| CO (1) | CO6821949A2 (es) |
| EC (1) | ECSP13013069A (es) |
| MX (1) | MX360666B (es) |
| PE (1) | PE20141070A1 (es) |
| TW (2) | TWI717552B (es) |
| WO (1) | WO2012155062A1 (es) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2665195B2 (ja) | 1995-05-19 | 1997-10-22 | 日本電気移動通信株式会社 | Ｍｃａシステムにおける移動局の個別番号表示方法 |
| US7767217B2 (en) * | 2006-03-14 | 2010-08-03 | Foresight Biotherapeutics | Ophthalmic compositions comprising povidone-iodine |
| TW201325601A (zh) * | 2011-09-16 | 2013-07-01 | Foresight Biotherapeutics Inc | 安定之普維酮－碘組成物 |
| EP2844227B1 (en) | 2012-05-03 | 2020-11-18 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| US9827191B2 (en) | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| EP4008355A1 (en) | 2012-05-03 | 2022-06-08 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
| US11596599B2 (en) | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
| JP6226998B2 (ja) * | 2013-02-15 | 2017-11-08 | 千寿製薬株式会社 | 抗菌性金属を含有するジフルプレドナートエマルション組成物 |
| JP6669499B2 (ja) | 2013-02-15 | 2020-03-18 | カラ ファーマシューティカルズ インコーポレイテッド | 治療用化合物 |
| CA2900680C (en) | 2013-02-20 | 2021-08-10 | Kala Pharmaceuticals, Inc. | Quinoline and quinazoline compounds and uses thereof for treating and/or preventing diseases |
| US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
| US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| AU2014342042B2 (en) | 2013-11-01 | 2017-08-17 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| US9463201B2 (en) | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| EP3302426A4 (en) | 2015-05-29 | 2018-12-05 | Sydnexis, Inc. | D2o stabilized pharmaceutical formulations |
| US11110112B2 (en) | 2016-02-18 | 2021-09-07 | Invirsa, Inc. | Methods for the use of 5'-adenosine diphosphate ribose (ADPR) |
| US11040062B2 (en) | 2016-04-14 | 2021-06-22 | Azura Ophthalmics Ltd. | Selenium disulfide compositions for use in treating meibomian gland dysfunction |
| US20190160003A1 (en) * | 2016-05-05 | 2019-05-30 | Veloce Biopharma, Llc | Compositions and methods for treatment of inflammation or infection of the eye |
| CA3036340A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| CA3036065A1 (en) | 2016-09-08 | 2018-03-15 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| AU2017324713B2 (en) | 2016-09-08 | 2020-08-13 | KALA BIO, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
| KR101935250B1 (ko) * | 2017-07-04 | 2019-01-04 | 김대황 | 요오드제 및 삼투성 미각제를 포함하는 눈, 구강용, 비강용 또는 흡입용 항바이러스 및 항균 조성물 |
| WO2019191026A2 (en) | 2018-03-27 | 2019-10-03 | Invirsa, Inc. | Methods for the use of 5'-adenosine diphosphate ribose (adpr) |
| JP7796016B2 (ja) | 2020-01-10 | 2026-01-08 | アズーラ オフサルミックス エルティーディー． | 組成物および過敏症のための指示 |
| CN113797164B (zh) * | 2020-06-17 | 2023-07-14 | 成都瑞沐生物医药科技有限公司 | 一种眼用制剂的载体或辅料及其制备方法和应用 |
| CN112305115B (zh) * | 2020-10-29 | 2022-08-23 | 诺峰药业(成都)有限公司 | 一种检测二氟泼尼酯眼用乳剂中的降解杂质及其含量的高效液相色谱方法 |
| KR20220062790A (ko) | 2020-11-09 | 2022-05-17 | 정춘영 | 포비돈 아이오딘계 소독액 |
| CA3203779A1 (en) * | 2021-01-21 | 2022-07-28 | Joon Youb Lee | Ophthalmic composition |
| EP4282402A4 (en) * | 2021-01-22 | 2025-04-23 | Chengdu Ruimu Biopharmaceuticals Co., Ltd. | OPHTHALMIC PREPARATION FOR THE TREATMENT OF MACULAR EDEMA, OPTIC NEURITIS AND NON-INFECTIOUS ENDOPHTHALMITITIS BY ADMINISTRATION OF EYE DROPS |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3886268A (en) * | 1972-05-30 | 1975-05-27 | Synergistics | Iodophor-steroid compound pharmaceutical compositions |
| US7767217B2 (en) * | 2006-03-14 | 2010-08-03 | Foresight Biotherapeutics | Ophthalmic compositions comprising povidone-iodine |
| MX372536B (es) * | 2008-06-12 | 2020-03-23 | Takeda Pharmaceuticals Co | Povidona yodada, un conservador alternativo novedoso para composiciones oftalmicas. |
| US20130177522A1 (en) * | 2009-12-15 | 2013-07-11 | Foresight Biotherapeutics, Inc. | Non-irritating opthalmic povidone-iodine compositions |
| TW201325601A (zh) * | 2011-09-16 | 2013-07-01 | Foresight Biotherapeutics Inc | 安定之普維酮－碘組成物 |
-
2012
- 2012-05-11 US US14/117,086 patent/US20150038473A1/en not_active Abandoned
- 2012-05-11 WO PCT/US2012/037563 patent/WO2012155062A1/en not_active Ceased
- 2012-05-11 EP EP12781920.9A patent/EP2707006B1/en active Active
- 2012-05-11 KR KR1020137032559A patent/KR101967938B1/ko not_active Expired - Fee Related
- 2012-05-11 TW TW106131033A patent/TWI717552B/zh not_active IP Right Cessation
- 2012-05-11 CA CA2835343A patent/CA2835343A1/en not_active Abandoned
- 2012-05-11 BR BR112013028735A patent/BR112013028735A2/pt not_active Application Discontinuation
- 2012-05-11 TW TW101116855A patent/TWI632914B/zh not_active IP Right Cessation
- 2012-05-11 AU AU2012253335A patent/AU2012253335B2/en not_active Ceased
- 2012-05-11 MX MX2013012971A patent/MX360666B/es active IP Right Grant
- 2012-05-11 JP JP2014510502A patent/JP6072009B2/ja not_active Expired - Fee Related
- 2012-05-11 PE PE2013002407A patent/PE20141070A1/es not_active Application Discontinuation
- 2012-05-11 CN CN201280034191.2A patent/CN103957922A/zh active Pending
- 2012-05-14 AR ARP120101708A patent/AR086399A1/es not_active Application Discontinuation
-
2013
- 2013-10-17 CL CL2013003016A patent/CL2013003016A1/es unknown
- 2013-12-09 EC ECSP13013069 patent/ECSP13013069A/es unknown
- 2013-12-09 CO CO13287528A patent/CO6821949A2/es not_active Application Discontinuation
-
2016
- 2016-09-02 AU AU2016222491A patent/AU2016222491A1/en not_active Abandoned
- 2016-12-22 JP JP2016248924A patent/JP6359619B2/ja not_active Expired - Fee Related
-
2018
- 2018-05-17 AU AU2018203492A patent/AU2018203492A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TWI717552B (zh) | 2021-02-01 |
| AU2018203492A1 (en) | 2018-06-07 |
| ECSP13013069A (es) | 2015-03-31 |
| CN103957922A (zh) | 2014-07-30 |
| KR101967938B1 (ko) | 2019-04-10 |
| MX2013012971A (es) | 2013-12-12 |
| CL2013003016A1 (es) | 2014-05-02 |
| JP6359619B2 (ja) | 2018-07-18 |
| AU2016222491A1 (en) | 2016-09-22 |
| US20150038473A1 (en) | 2015-02-05 |
| TWI632914B (zh) | 2018-08-21 |
| EP2707006B1 (en) | 2019-07-03 |
| JP2014516954A (ja) | 2014-07-17 |
| AU2012253335A1 (en) | 2013-05-02 |
| EP2707006A4 (en) | 2014-09-24 |
| KR20140045375A (ko) | 2014-04-16 |
| MX360666B (es) | 2018-11-13 |
| JP2017095474A (ja) | 2017-06-01 |
| AU2012253335B2 (en) | 2016-08-04 |
| WO2012155062A1 (en) | 2012-11-15 |
| JP6072009B2 (ja) | 2017-02-01 |
| EP2707006A1 (en) | 2014-03-19 |
| CA2835343A1 (en) | 2012-11-15 |
| TW201811340A (zh) | 2018-04-01 |
| AR086399A1 (es) | 2013-12-11 |
| TW201311256A (zh) | 2013-03-16 |
| CO6821949A2 (es) | 2013-12-31 |
| BR112013028735A2 (pt) | 2017-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20141070A1 (es) | Composiciones estables de povidona yodada con antiinflamatorios esteroideos o no esteroideos | |
| JP2014516954A5 (es) | ||
| PE20141676A1 (es) | Composiciones de yodo-povidona estable | |
| NZ734050A (en) | Compositions comprising povidone-iodine | |
| PE20121498A1 (es) | Composiciones oftalmicas no irritantes de povidona-yodo | |
| CL2021001042A1 (es) | Nuevos compuestos antihelmínticos | |
| PE20160665A1 (es) | Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x | |
| AR091413A1 (es) | Formulacion de anticuerpos | |
| AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
| AR080368A1 (es) | Disoluciones acuosas transparentes de acetonido de fluocinolona para el tratamiento de la inflamacion de oido | |
| PE20120665A1 (es) | Formulacion subcutanea de anticuerpo anti-her2 | |
| MX2018011278A (es) | Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina. | |
| MX2019003906A (es) | Composiciones parasiticidas que comprenden un agente activo de isoxazolina, sus metodos y usos. | |
| MX369385B (es) | Productos para cicatrizar heridas tisulares. | |
| MX340962B (es) | Agentes de enlace a receptor de canabinoide, composiciones y metodos. | |
| AR069792A1 (es) | Composicion agroquimica y metodo para preparar la misma | |
| SG10201900504XA (en) | Pharmaceutical composition comprising glutarimide derivatives and use thereof in the treatment of eosinophilic diseases | |
| CL2011003065A1 (es) | Formulacion vesicular que comprende uno o mas fosfolipidos y uno o mas surfactantes no ionicos, libre de cualquier agente farmaceuticamente activo, util para el tratamiento del dolor asociado con osteoartritis. | |
| EA201891649A1 (ru) | C-3 и c-17 модифицированные тритерпеноиды в качестве ингибиторов вич-1 | |
| BR112013028786A2 (pt) | método e composição de tratamento de sementes | |
| PE20150345A1 (es) | Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa 11b-hidroxiesteroide tipo 1 (11b-hsd1) o sal farmaceuticamente aceptable del mismo, metodo para producir el mismo, y composicion farmaceutica que contiene el mismo como ingrediente activo | |
| CO6640318A2 (es) | Formas de dosificación oral de bendamustina | |
| MX2019015927A (es) | Composiciones para administración de fármacos y métodos de uso de las mismas. | |
| AR092691A1 (es) | Composicion farmaceutica que comprende rebamipida | |
| BR112012029697A2 (pt) | polissacarídeo da semente de tamarindo para uso no tratamento de doenças inflamatórias |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |